<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2884">
  <stage>Registered</stage>
  <submitdate>25/08/2010</submitdate>
  <approvaldate>25/08/2010</approvaldate>
  <nctid>NCT01190410</nctid>
  <trial_identification>
    <studytitle>Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol</studytitle>
    <scientifictitle>An Open-label, Multicenter Study to Assess the Safety of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease Who Completed C87035 (NCT00899678) or Who Were Terminated From C87035</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CR0012</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Crohn's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Crohn's disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - certolizumab pegol
Treatment: drugs - certolizumab pegol

Experimental: Certolizumab pegol: high-dose group - 400 mg administered subcutaneously every 4 weeks for subjects = 40 kg or 200 mg for subjects 20 to &lt; 40 kg

Experimental: Certolizumab pegol: low-dose group (weight adjusted) - 200 mg administered subcutaneously every 4 weeks for subjects = 40 kg or 200 mg for subjects 20 to &lt; 40 kg


Treatment: drugs: certolizumab pegol
400 mg administered subcutaneously every 4 weeks for subjects = 40 kg or 200 mg for subjects 20 to &lt; 40 kg

Treatment: drugs: certolizumab pegol
200 mg administered subcutaneously every 4 weeks for subjects = 40 kg or 100 mg for subjects 20 to &lt; 40 kg

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of subjects reporting at least one Treatment-emergent Adverse Event (TEAE) during study treatment (up to 416 weeks) - Treatment emergent adverse events will be summarized descriptively by primary system organ class (SOC), high level term, and preferred term (PT).</outcome>
      <timepoint>During study treatment (up to 416 weeks)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of subjects discontinuing treatment due to a Treatment-emergent Adverse Event (TEAE)</outcome>
      <timepoint>During study treatment (up to 416 weeks)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of subjects who develop anti-nuclear antibodies during the study</outcome>
      <timepoint>During study treatment (up to 416 weeks)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of subjects who develop double-stranded deoxyribonucleic acid (dsDNA) antibodies during the study</outcome>
      <timepoint>During study treatment (up to 416 weeks)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of subjects in clinical remission - Percentage of subjects in clinical remission (clinical remission is defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score = 10)</outcome>
      <timepoint>During study treatment (up to 416 weeks)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subject who completed the C87035 study (NCT00899678) through Week 62 or assessments
             when their participation in C87035 was terminated when the study was stopped by UBC

          -  Subject completed all assessments required for Week 62/Visit 23 at the time of
             termination

          -  Subjects maintain stable regimen of concomitant medications for Crohn's Disease (CD)
             throughout study</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>17</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subject who did not complete the C87035 study (Week 62 Visit), was terminated or did
             not complete all of the Week 62 assessments when their participation from C87035 was
             terminated when the study was stopped by UCB but did not complete all assessments
             required for Week 62/Visit 23 at the time of termination</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>16</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>301 - Parkville</hospital>
    <postcode> - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>UCB Pharma</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the long-term safety and tolerability of
      certolizumab pegol (CZP) treatment in children and adolescents with moderately to severely
      active Crohn's disease. Secondarily, to assess the long-term efficacy, pharmacokinetics (PK),
      and immunogenicity of CZP treatment in children and adolescents with moderately to severely
      active Crohn's disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01190410</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>UCB Clinical Trial Call Center</name>
      <address>+1 877-822-9493 UCB</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>